JPMorgan analyst Brian Cheng notes that Kyverna Therapeutics presented an update at the EULAR meeting from its auto anti-CD19 CAR-T program KYV-101 and the firm believes the weakness in shares today is “an overreaction centered around disease recurrence in one lupus patient who was treated with a sub-therapeutic dose.” Investors’ concerns of recurrence risks should not be anchored to this single observation, argues the analyst, who reiterates an Overweight rating on Kyverna shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYTX:
- Kyverna Therapeutics Showcases CAR T-cell Therapy Progress at EULAR
- J.P. Morgan Predicts up to 210% Gains for These 2 ‘Strong Buy’ Stocks
- Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
- Kyverna Therapeutics reports Q1 EPS ($1.12), consensus (84c)
- Kyverna Therapeutics added to Analyst Focus List at JPMorgan